Bio Total Current Liabilities from 2010 to 2025
| TECH Stock | USD 75.01 0.24 0.32% |
Total Current Liabilities | First Reported 1989-09-30 | Previous Quarter 142.1 M | Current Value 161.3 M | Quarterly Volatility 49.5 M |
Check Bio Techne financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Bio Techne's main balance sheet or income statement drivers, such as Depreciation And Amortization of 134.9 M, Total Revenue of 1.4 B or Gross Profit of 929.4 M, as well as many indicators such as Price To Sales Ratio of 6.9, Dividend Yield of 0.0049 or PTB Ratio of 6.78. Bio financial statements analysis is a perfect complement when working with Bio Techne Valuation or Volatility modules.
Bio | Total Current Liabilities |
Latest Bio Techne's Total Current Liabilities Growth Pattern
Below is the plot of the Total Current Liabilities of Bio Techne Corp over the last few years. Total Current Liabilities is an item on Bio Techne balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Bio Techne Corp are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. It is the total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations. Bio Techne's Total Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Bio Techne's overall financial position and show how it may be relating to other accounts over time.
| Total Current Liabilities | 10 Years Trend |
|
Total Current Liabilities |
| Timeline |
Bio Total Current Liabilities Regression Statistics
| Arithmetic Mean | 100,291,562 | |
| Geometric Mean | 69,221,667 | |
| Coefficient Of Variation | 62.85 | |
| Mean Deviation | 54,163,867 | |
| Median | 106,668,000 | |
| Standard Deviation | 63,033,684 | |
| Sample Variance | 3973.2T | |
| Range | 190.6M | |
| R-Value | 0.94 | |
| Mean Square Error | 482.7T | |
| R-Squared | 0.89 | |
| Slope | 12,466,458 | |
| Total Sum of Squares | 59598.7T |
Bio Total Current Liabilities History
About Bio Techne Financial Statements
Investors use fundamental indicators, such as Bio Techne's Total Current Liabilities, to determine how well the company is positioned to perform in the future. Although Bio Techne's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
| Last Reported | Projected for Next Year | ||
| Total Current Liabilities | 183.3 M | 192.5 M |
Currently Active Assets on Macroaxis
When determining whether Bio Techne Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bio Techne's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bio Techne Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bio Techne Corp Stock:Check out the analysis of Bio Techne Correlation against competitors. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bio Techne. If investors know Bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bio Techne listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.32) | Earnings Share 0.98 | Revenue Per Share | Quarterly Revenue Growth 0.045 | Return On Assets |
The market value of Bio Techne Corp is measured differently than its book value, which is the value of Bio that is recorded on the company's balance sheet. Investors also form their own opinion of Bio Techne's value that differs from its market value or its book value, called intrinsic value, which is Bio Techne's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bio Techne's market value can be influenced by many factors that don't directly affect Bio Techne's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bio Techne's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bio Techne is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bio Techne's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.